Oncolytic-adenovirus-expressed RNA interference for cancer therapy.
BACKGROUND
RNA interference (RNAi) has generated considerable excitement for its potential cancer therapeutic applications. Because of the difficulties in delivering a large amount of siRNA to cancer cells and the short half-life of siRNA, it is important to choose an efficient delivery system for transduction of siRNA into target cells. Oncolytic adenovirus offers a better platform by virtue of its high transfection efficiency and selective replication in cancer cells.


METHODS
This review focuses on the synergism between oncolytic adenovirus and siRNA antitumor responses, and discusses recent progresses in oncolytic-adenovirus-expressed siRNA.


RESULTS
siRNA-expressing oncolytic adenovirus can generate a significantly enhanced antitumor effect through gene knockdown and viral oncolysis.


CONCLUSIONS
Due to its potency and target specificity, using siRNA delivery by oncolytic adenovirus has generated much excitement and will open new avenues for treatment of human cancer.
Pei
Dong-Sheng
DS
Xuzhou Medical College, Laboratory of Biological Cancer Therapy, 84 West Huai-hai Road, Xuzhou, Jiangsu 221002, PR China. jnzheng@xzmc.edu.cn
Di
Jie-Hui
JH
Chen
Fei-Fei
FF
Zheng
Jun-Nian
JN
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D009369:Neoplasms / Q000235:genetics / Q000628:therapy* / Q000821:virology; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses / Q000235:genetics*; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000096:biosynthesis*
D034741:RNA, Small Interfering